Phaseline

Companies › CellSight Technologies

CellSight Technologies: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[18F]F-AraG
Radiolabeled substrate for deoxyguanosine kinase (dGK) and deoxycytidine kinase (dCK), bot
DGK, DCKPhase 2Covid19Oct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04815096[18F]F-AraGPhase 2Covid19Infectious diseaseOct 2027

Targets

DGK (1) DCK (1)

Companies with the same targets

Trethera Jiangsu Hansoh Pharmaceutical

Companies built like this

Amplexd Therapeutics Sano Chemicals Hyundai Bioscience KTH Biopharma Frantz Viral Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.